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OBJECTIVES:Multiple sclerosis (MS) and Alzheimer’s Disease (AD) are chronic and
progressive diseases that have the potential to impose a significant burden on both
caregivers and the immediate families of patients. Extensive literature has docu-
mented MS and AD caregiver burden on physical and mental health; but there are
no direct comparisons of MS and AD caregivers. This study examined the extent of
MS caregiver burden compared to non-caregivers and caregivers of AD patients.
METHODS:Datawere obtained from the 2009National Health andWellness Survey
administered online to a US representative adult sample (N75,000). Respondents
reported health status, quality of life, work productivity, healthcare utilization and
caregiver status. Multivariable regressions, adjusting for key characteristics (e.g.,
age, gender, marital status, depression), were conducted to explore differences
between MS caregivers (n215) vs. non-caregivers (n69,224), as well as MS care-
givers vs. AD caregivers (n1,341). Rate ratios (RR) and regression weights (b) are
reported. RESULTS: Compared to non-caregivers, MS caregivers had significantly
greater activity impairment (RR1.41; p0.01) and poorer mental (b1.44;
p0.015), physical (b1.96; p0.002), and health utility scores (b0.03;
p0.002), along with more traditional healthcare provider visits (RR1.46;
p0.0001), ER visits (RR2.16; p0.0001), and hospitalizations (RR2.20; p0.001)
after covariate adjustment. Compared to AD caregivers, MS caregivers had greater
activity impairment (RR1.29; p0.044) and more ER visits (RR1.60; p0.017) and
hospitalizations (RR1.92; p0.008) after covariate adjustment. Work productivity
differences were not observed in comparison with either group, potentially due to
the small number of employed MS caregivers in the sample (n126).
CONCLUSIONS:MS caregivers had significantly more burden compared with non-
caregivers. In addition, the results suggest an even greater burden to these indi-
viduals than observed among AD caregivers. The results of this analysis of a na-
tional survey reveal the hidden toll of those providing care for MS patients and
highlights the need to recognize their burden so that appropriate measures can be
implemented.
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MULTIPLE SCLEROSIS PATIENTS REPORT IMPROVEMENTS IN FATIGUE AND
COGNITIVE FUNCTIONING AFTER ONE YEAR OF NATALIZUMAB TREATMENT
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OBJECTIVES: To evaluate changes in patient reported fatigue and cognitive func-
tion after one year of natalizumab treatment in multiple sclerosis (MS) patients.
METHODS: The study population consists of MS patients initiating natalizumab
treatment who agreed to participate in a 12 month longitudinal study. Patients
reported experiences with natalizumab using validated patient-reported outcome
(PRO) measures prior to natalizumab treatment initiation (BL) and after 3rd, 6th and
12th infusion. The current analysis reports change in fatigue and cognition from
baseline through the 12th natalizumab infusion. Fatigue was measured by the
5-question Modified Fatigue Impact Scale-5 (MFIS-5, score range 0-20) with lower
scores indicating lower impact of fatigue on physical, cognitive, and psychosocial
functioning; cognitive functionwasmeasured by the 6-questionMedical Outcomes
Study Cognitive Functioning Scale (MOS-Cog Scale, score range 6-36) with higher
scores indicating better reasoning skills, memory, concentration, ability to start
several actions at one time and ability to react to what is said or done. Regression
analysiswas used to control for BL covariates such as age, years sinceMSdiagnosis,
number of natalizumab infusions received, disability and functional status, num-
ber of MS drugs used prior to natalizumab and comorbidity burden. RESULTS:Data
for 324 patients who completed the BL through 12th infusion assessments are re-
ported. Themean age was 46.5 (SD10.4) and themajority of patients were female
(77.8%). The mean number of years since MS diagnosis was 10.16 (SD8.23). On
average, MFIS scores decreased significantly (BL 12.362.18; 12th infusion score
11.162.18, p0.001) and MOS-Cog scores increased significantly over time (BL
25.121.51; 12th infusion score 26.191.97, p0.001) after controlling for
covariates. CONCLUSIONS: MS patients reported improvements in fatigue and
overall cognitive function after one year of natalizumab treatment.
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OBJECTIVES: There is abundant evidence that individuals with Multiple Sclerosis
(MS) have compromised quality of life (QOL) and work productivity, and increased
healthcare resource use compared to individuals without MS. The possible associ-
ation between subjects’ self-reported severity of disease and these variables in an
MSpopulation has only recently been explored. Patient perceptions of disease have
been increasingly recognized as an important factor in healthcare resource use.
The objective of this study was to analyze the association between perceived se-
verity of disease (mild, moderate, or severe) and symptoms, quality of life, work
productivity, and healthcare resource use in individuals with MS.METHODS: Data
from respondents reporting anMS diagnosis were obtained from the 2009 National
Health andWellness Survey (NHWS), an Internet-based annual study of the health-
care attitudes and behaviors of a US representative adult sample. The survey in-
cluded questions about demographics, disease severity, symptoms, quality of life,
work productivity, and healthcare resource use. RESULTS: In the 2009 NHWS
study, 536 reported an MS diagnosis. MS respondents characterized the severity of
their disease as follows: mild (n206; 38.4%), moderate (n268; 50%); and severe
(n62; 11.6%). There were no differences in the number of years since diagnosis
among the groups but there were significantly more men in the severe group. As
perceived severity increased among MS patients (mild, moderate, severe), symp-
tom severity generally increased, QOL decreased (SF-12 Physical Component
Score), percent with full-time employment decreased, loss of work productivity
and presenteeism increased among those reporting employment and healthcare
resource use increased (ER visits and hospitalizations). CONCLUSIONS: Generally,
those withmore severe illness reported greater impairment. However, for many of
the variables examined, more significant differences were found between patients
who perceive their disease severity as mild and moderate than those patients
reporting moderate and severe disease severity.
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NEURO-DEVELOPMENTAL DISORDER
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OBJECTIVES: This study evaluated and examined the relationship between parent-
ing stress in caring for children diagnosed with a neuro-developmental disorder.
METHODS: A cross-sectional study was conducted by using a self-administered
questionnaire distributed through schools that provide services for children with
developmental disorder. Parents with children aged 3-18 years and diagnosedwith
a neuro-developmental disorder were requested to complete the survey. Previ-
ously validated scales, the Parenting Stress Index (PSI) and the Columbia Impair-
ment Scale (CIS) were used along with scales to measure parent and child’s char-
acteristics. Data was coded and analyzed using SAS v9.2 by performing descriptive
and regression analyses. RESULTS: A total of 150 surveys were received from 4
schools net response rate (26.5%). Themean parent’s age was 45.7(6.4) years with
mothers being higher portion of respondents (84%) and most (90%) were married.
Mean PSI reported was 96.9(23.9) and clinically significant (85). Higher PSI was
attributed to the difficult child (DC) subscale (35.610.4) followed by parental dis-
tress (PD) subscale (31.89.3) and the parent-child dysfunctional interactions
(PCDI) subscale (30.28.5). Reliability coefficients for the PSI was high (0.91), includ-
ing the subscales (DC0.85, PD0.87, and PCDI0.8). Mean summary score for CIS
was 19.1(10.7) with a reliability coefficient of 0.9. A multiple regression analysis
indicated a positive relationship of PSI with developmental impairment (CIS,
1.43 p0.0001) after controlling for child’s characteristics (age, gender, diagno-
sis, number of children, child with similar diagnosis, relationship of parent) and
parent’s characteristics (age, race, education, employment status, income and ex-
isting disorder). CONCLUSIONS: Children with severe developmental impairment
may lead to greater stress for parents. Untreated stress can cause diseases, such as
heart diseases and depression. Interventions controlling stress is the key to im-
proving parents’ quality of life for those that care for children with neuro-develop-
mental disorders.
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OBJECTIVES: The impact of Parkinson’s disease (PD) on the quality of life of both
patients and their carers has not been well documented. This study describes the
health status of both PD patients and caregivers asmeasured on a genericmeasure
of health status (SF-12), and then explores to what extent patient self-reported
health, as measured on the disease-specific Parkinson’s Disease Questionnaire
(PDQ-39), is associated with carer strain and self-reported quality of life.
METHODS:Apostal surveywas carried out of both patients and caregivers through
local branches of Parkinson’s UK. Questionnaire packs were sent to those on the
database with a diagnosis of PD. Patients were asked to give the carer question-
naire to theirmain caregiver, if they had one. RESULTS: Results suggest that PD has
substantial adverse effects on both the physical (measured by the Physical Com-
ponent Summary, PCS) andmental well-being of patients (measured by theMental
Component Summary, MCS) when compared with population norms. Most strik-
ingly PD patients PCS scores fall within the lowest 10% of results, compared with a
wider general population sample. While carer physical health was not found to be
substantially different from that of the general population, emotional health was
severely compromised with a MCS score that places them in the lowest 22% of the
population. Regression analysis suggests that the major predictors of carer strain
are the PDQ scales of mobility and social support. Carer strain was found to be
closely associated with carer mental health. CONCLUSIONS: PD impacts on the
well being of both patients and caregivers; the data provide evidence that the
health status of the patient, in particular their physical health, has a significant
impact on the well-being of their caregivers.
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OBJECTIVES: To describe key characteristics of members of the online, USA-based
PatientsLikeMe® Epilepsy Community, by comparison with a widely-used USA
claims database, PharMetrics®, and to assess the impact of epilepsy on patients’
lives using patient-reported data, collected through PatientsLikeMe®. METHODS:
The PatientsLikeMe® Epilepsy Community allows patients with epilepsy to record
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their characteristics and monitor treatment and outcomes. The system allows
longitudinal entry of well-known Patient Reported Outcome instruments (e.g. QO-
LIE-31-P, HADS), treatments, symptoms, and seizure frequency and severity.
RESULTS: By September 2010, 2613 patients had registered; 1838 (70.3%) patients
with a reported diagnosis of epilepsy were analyzed. The PatientsLikeMe® Epilepsy
Community tends to over-represent females compared with PharMetrics® (71.7%
vs. 53.6%) and 20–50 year old patients, reflecting online user demographics. The
proportions of treated patients receiving polytherapy or newer AEDs were also
greater in PatientsLikeMe® versus PharMetrics® (53.4% vs. 29.2%; 82.4% vs. 66.4%,
respectively). Regional coverage of PatientsLikeMe® members appeared closer to
US census than PharMetrics®. Patient-reported data from PatientsLikeMe® re-
flected the significant burden of epilepsy on patients’ lives. Patients experiencing
1 seizure during the last 4 weeks reported significantly lower quality of life (QoL)
and higher levels of depression and anxiety than those not reporting seizures (all
p-values 0.005). This was even more pronounced in patients reporting 1 gener-
alized tonic-clonic seizure (all p-values 0.001). Driving status was clearly im-
pacted by epilepsy; 50.6% in the PatientsLikeMe® sample did not drive (86.2% of
these because of epilepsy) and 37.4% of drivers limited their driving because of
epilepsy. Patients with driving limitations reported lower health-related QoL and
higher levels of anxiety and depression (all p-values 0.0001). CONCLUSIONS: By
sharing their records online,members of the PatientsLikeMe® Epilepsy Community
provide researchers with a unique source of information. Exploring these data
provides insight into the disease burden, treatment patterns and associated out-
comes. UCB-sponsored.
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HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS WITH DYSPORT IN
CERVICAL DYSTONIA
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In a multicenter, double-blind trial, Dysport 500 units was compared to placebo
in the treatment of cervical dystonia. The primary efficacy response was eval-
uated using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).
Pain was evaluated with the Pain subscale of the TWSTRS and a self-reported
pain visual analog scale (VAS). HRQL was assessed using the SF-36 Health Sur-
vey (SF-36). OBJECTIVES: To evaluate improvements in health-related quality of
life (HRQL) with in patients with cervical dystonia enrolled in a randomized clinical
trial with Dysport™ (also known as abobotulinumtoxinA for Injection in the United
States). METHODS: Eighty patients were randomly assigned to receive one treat-
ment with Dysport 500 units or placebo. Participants were assessed at baseline and
weeks 2, 4, 8, 12, 16, and 20 after treatment. To evaluate HRQL, changes from
baseline toWeek 8 on the 8 SF-36 domains, the TWSTRS Pain subscale, and the pain
VAS were compared. RESULTS: TWSTRS total scores were significantly improved
with Dysport at weeks 4, 8, and 12 (P  0.013 when compared with placebo). Im-
provements from baseline to week 8 were seen for all 8 SF-36 domains in the
Dysport group. The largest improvements occurred in the Role–Physical and Bodily
Pain domains. The placebo group showed some decrease (worsening) in Physical
Functioning and little to no change in other SF-36 domains. The differences in
mean change scoreswere statistically significant between the Dysport and placebo
for 5 of the 8 domains (Physical Functioning, Role–Physical, Bodily Pain, General
Health, and Role–Emotional [P  0.03 for all]). Improvement in the Bodily Pain
domain was also supported by significant improvements in the TWSTRS Pain sub-
scale and the pain VAS at week 4. CONCLUSIONS: The data suggest that HRQL is
improved with Dysport, particularly pain improvement and in the SF-36 Physical
Functioning and Role–Physical domains.
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IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE
SCLEROSIS PATIENTS
Stephenson JJ1, Agarwal SS2, Kern DM1, Kamat SA1
1HealthCore, Inc., Wilmington, DE, USA, 2Biogen Idec, Wellesley, MA, USA
OBJECTIVES: To assess the change in general health-related quality of life (HRQoL)
of multiple sclerosis (MS) patients after one year of natalizumab treatment in the
usual care setting. METHODS: MS patients, newly initiating natalizumab, were
recruited to participate in a longitudinal observational study to assess general
HRQoL using the SF-12v2 prior to natalizumab initiation (baseline, BL) and after the
3rd, 6th and 12th infusions. Higher physical component summary scores (PCS) and
mental component summary scores (MCS) on the SF-12v2 indicate better HRQoL.
Statistical regressionmodels were used to evaluate changes in PCS andMCS scores
from BL through the 12th infusion after controlling for BL covariates such as age,
years sinceMS diagnosis, number of natalizumab infusions received, disability and
functional status, number of MS drugs used prior to natalizumab and comorbidity
burden. RESULTS: Data for 324 patients who completed the baseline through 12th
infusion assessments are reported. The mean age was 46.5 (SD10.4) and the ma-
jority of patients were female (77.8%). The mean number of years since MS diag-
nosis was 10.16 (SD8.23). The adjusted PCS score improved significantly from
baseline (BL 34.25, 12th infusion 36.66; p0.001); similar significant improvements
were observed in the adjusted MCS scores (BL 43.13, 12th infusion 46.77; p0.001).
CONCLUSIONS: Patients reported improvements in general HRQoLmeasures after
one year of natalizumab treatment in the usual care setting. These results are
consistent with results from pivotal clinical trials and document the beneficial
impact of natalizumab on HRQoL in MS patients.
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OBJECTIVES: To develop a single conceptual model of the impact of epilepsy on
adult and pediatric patients with partial onset seizures to guide the identification
of endpoints in clinical trials of new anti-epileptic treatments.METHODS: A liter-
ature review to identify qualitative research investigating the impact of partial
onset seizures on adult and paediatric patients’ lives. Structured Embase/Medline
searches identified 167 abstracts which were screened to identify primary qualita-
tive research among adult and/or pediatric epilepsy patients. Publications were
excluded if they: did not include partial onset seizure patients (with or without
generalised seizures); focused on surgical treatment, were not qualitative research;
were conducted outside of North America/Europe; focused on epilepsy as a sec-
ondary condition. 12 adult and 8 pediatric qualitative studies were identified. Rel-
evant data were extracted into structured tables. Results from both samples were
synthesised into a conceptual model by two experienced qualitative researchers.
RESULTS: Twenty-three concepts were identified from the reviewed literature.
Concepts were largely universal between adult and pediatric patients, although
content of concepts varied between adults and pediatric, for example paediatric
relationship concerns were focused on rejection in friendships and trouble de-
veloping relationships. For adults the concerns were problematic relationships
with spouse or partner, fulfilling family roles and problems having children.
CONCLUSIONS: The conceptual model identifies important impacts of epilepsy
from the patient perspective. The model also demonstrates areas of patients’ lives
thatmay potentially be enhanced through improvement of epilepsy symptoms. As
a result, the model allows for concepts of concern to both adult and pediatric
patients to be identified and explored as potential patient-reported endpoints in
clinical trials of new antiepileptic treatments.
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OBJECTIVES: To describe health-related quality of life (HRQoL) and health utility of
persons with hemophilia B, and to determine the association of these measures
with self-reported joint pain and motion limitation. METHODS: The prospective,
longitudinal Hemophilia Utilization Group Study (HUGS-Vb) recruited participants
with hemophilia B from six U.S. Hemophilia Treatment Centers from June 2009 to
September 2010. At initial interview, participants or their parent(s) answered ques-
tions regarding demographic and clinical characteristics, HRQoL, health utility and
self-reported joint pain and motion limitation. HRQoL measures included Short
Form-12 (SF-12) for adults and PedsQL for children. Health utility measures used
were EQ-5D (adults) and visual analog scale (VAS). RESULTS: Seventy-seven par-
ticipants (48% adults) were recruited. Adultmean SF-12mental (MCS-12) and phys-
ical (PCS-12) component scores were 54.3 (6.13) and 47.1 (11.1) respectively.
Participants with mild/moderate hemophilia (mean50.49.0) had significantly
better PCS-12 scores than those with severe hemophilia (mean42.612.4)
(P0.0390). Mean EQ-5D and VAS scores were 0.85 (0.16) and 85.5 (11.1) respec-
tively, with no significant differences between severity groups. PCS-12 and EQ-5D
each negatively correlated with self-reported joint pain (PCS-12:P0.0001, EQ-5D:
P0.0017) andmotion limitation (PCS-12:P0.0001, EQ-5D:P0.0081); better HRQoL
was associated with less severe pain or limitation. Pediatric mean total PedsQL
score was 85.6 (11.2) with physical (PF) and psychosocial functioning summary
scores of 92 (14.9) and 82 (13.1) respectively. Mean VAS score was 88.6 (14.3).
No significant differences were found between severity groups. PF and VAS scores
each negatively correlated with self-reported joint pain (PF:P0.0127, VAS:
P0.0245) and motion limitation (PF:P0.0009, VAS:P0.0015). CONCLUSIONS:
While previous HRQoL studies have examined hemophilia A and its associated
clinical aspects, this is the first focusing on the hemophilia B population. As hemo-
philia A and B may have different clinical manifestations, HRQoL data on hemo-
philia B can help define disease burden in this group. One limitation is the current
small sample size, which will increase as additional participants continue to be
enrolled.
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OBJECTIVES:Quality of life (QoL) remains an important consideration in the care of
patients presenting with chronic neuromuscular disorder (NMD). The factor struc-
ture of the SF-36 was evaluated in patients with NMD in order to determine the
appropriateness of this instrument to assess QoL in this clinical population.
METHODS: Confirmatory factor analyses were conducted on self-report SF-36 data
from 245 individual’s diagnosedwith NMD. Six structural models of the SF-36 were
evaluated against data. RESULTS: The underlying factor structure of the SF-36 in
NMD was observed to be consistent with contemporary theoretical models of the
instrument. The traditional measurement model of SF-36, however, performed
comparatively poorly. CONCLUSIONS: The use of the SF-36 in individuals with
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